IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Post-LOE

ibuprofen and pseudoephedrine hydrochloride

Aurobindo Pharma

ANDAORALTABLET

Approved

Mar 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE (ibuprofen and pseudoephedrine hydrochloride) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for these symptoms associated with the common cold, flu:. First approved in 2023.

Drug data last refreshed 1w ago

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (2)

these symptoms associated with the common cold flu:

Clinical Trials (1)

NCT03429738Phase 1Completed

Single-Dose Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride Tablets

Started Apr 2014

66 enrolled

Pain, HeadPain, AcutePain, Back+1 more

Worked on IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.